Hy Stor Energy Strategic Partnership with Key Gulf Coast Port Becomes First to Deliver Renewable Hydrogen Access for Manufacturing, Industrial Applications, Port Operations and Long Duration Energy Storage
29.6.2022 16:00:00 EEST | Business Wire | Press release
Hy Stor Energy LP (Hy Stor Energy), a company pioneering renewably produced green hydrogen and energy storage at scale in Mississippi, announced today a strategic partnership with the Hancock County Port and Harbor Commission (HCPHC) to provide zero-carbon, zero-methane hydrogen to Port Bienville Industrial Park and Stennis International Airport, accelerating the decarbonization of land, air, sea, and space. Through this partnership, Port Bienville will be the first port in the Gulf Region to integrate renewable hydrogen as a fuel into its operations. During the first phase of the partnership, the hydrogen hub is expected to produce an estimated 350 tons/day (320,000 kg/day) of renewable hydrogen and store more than 71,000 tons (69 million kg) of hydrogen in underground salt caverns.
The existing Port Bienville infrastructure will expand to better enable decarbonization efforts and will be in a premium location to allow for new manufacturing of circular hydrogen infrastructure – the first of its kind in the United States. Port customers striving to meet their respective ESG goals will be able to create new industry jobs – strengthening the port’s position as a workforce hub of industry and technology.
Together Hy Stor Energy and HCPHC will work to sustain economic growth in Hancock County and provide reliable, renewable, and carbon-free energy to coastal Mississippi and the Gulf Coast Region. Currently, Port Bienville Industrial Park is home to leading companies including SABIC Innovative Plastics, DAK Americas, SNF Polychemie, Calgon Carbon, and Jindal Tubular USA, among others.
“Hancock County Port and Harbor Commission is committed to growing economic opportunities in a responsible way,” said CEO Bill Cotter, HCPHC. “Hydrogen is emerging as a way to cut carbon emissions in energy-intensive sectors like manufacturing and transportation. As we continue to grow our maritime, rail and aerospace operations, hydrogen provides options to fuel growth and innovations.”
Hancock County, Mississippi, is located in a prime position on the Gulf Coast with access to inland waterways, rail, and highway corridors. Located a short distance east of New Orleans, Hancock County is home to Port Bienville, Stennis International Airport, and NASA’s John C. Stennis Space Center, which enable domestic and global reach. Hy Stor Energy will develop the renewable hydrogen from its Clean Hydrogen Hub from offices in Jackson, Gulfport, and Kiln at Port Bienville.
“We are proud to partner with the Hancock County Port and Harbor Commission to provide renewable hydrogen access to Port Bienville Industrial Park, including some of the world’s most recognized companies,” said Laura L. Luce, CEO of Hy Stor Energy. “This partnership provides a strategic opportunity for companies who are looking for innovative ways to meet their decarbonization goals to co-locate operations in Hancock County in the Gulf Region. We are focused on developing zero-carbon, zero-methane renewable hydrogen technology for a broad array of applications, including manufacturing and industrial processes, port operations, and long-duration energy storage that will benefit communities while providing reliable clean power.”
The Richton Dome in Perry County, Mississippi was a previously selected expansion location for the U.S. Strategic Petroleum Reserve, and its central U.S. and Gulf Coast location will serve as a Strategic Hydrogen Reserve connected to new, dedicated, dual bi-directional pipelines that will extend from Richton in Perry County to Hancock County and the Port of Bienville. Hy Stor Energy’s infrastructure will enable 24x7 renewable green hydrogen to be delivered to and from the port in addition to underground salt storage domes within approximately 100 miles of the port – providing resilient, zero-carbon, zero-methane hydrogen on demand. These long-term renewable hydrogen storage salt domes in Richton will be interconnected to new pipeline infrastructure and will further connect multiple salt domes from Louisiana to Jackson, Mississippi to Simpson County to Smith County to Perry County - and on to Hancock County to provide resilient, clean energy to coastal communities as well. This will allow Mississippi to serve as a U.S. centrally located and highly connected strategic hydrogen reserve to connect multiple underground salt domes with Richton where the first salt dome caverns will be developed purpose-built for the safe storage of renewable hydrogen at scale.
For more information about Hy Stor Energy, please visit www.hystorenergy.com.
About Hy Stor Energy
Hy Stor Energy is facilitating the transition to a fossil-free energy environment by developing and advancing renewable hydrogen at scale through the development, commercialization, and operation of renewable hydrogen hub projects. The company defines green hydrogen as only that which has produced from renewables -- as set forth by the Green Hydrogen Organisation. Large, fully integrated projects produce, store, and deliver 100% carbon-free, energy, providing customers with safe and reliable renewable energy on-demand. Developed as part of an integrated hub, these projects couple on-site renewable hydrogen production with integrated long-duration storage and distribution – using scale to reduce costs. Hy Stor Energy, led by energy storage industry and hydrogen technology veteran Laura L. Luce, has an innovative team with deep expertise and is positioned as a leader in the renewable hydrogen revolution. For more information, please visit www.hystorenergy.com.
About Hancock County Port and Harbor Commission
The Hancock County Port and Harbor Commission was established in 1963 to lead the county’s economic development activities. Stennis International Airport and Port Bienville Industrial Park are home to 30 companies with more than 1,000 employees. For more information visit www.portairspace.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005311/en/
Contact information
Hy Stor Energy Media Contact
Brad Carl
On behalf of Hy Stor Energy
brad@teamsilverline.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom